Senores PharmaceuticalsNSE:SENORES -0.39%18 EBITDA Margin % is 37.19% as of Mar. 2026, which is 36% above its 10-year median of 27.36. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Senores Pharmaceuticals ranks better than 90.16% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Senores Pharmaceuticals EBITDA Margin % Related Terms
Senores Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SENORES vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals (NSE:SENORES) has a EBITDA Margin % of 37.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Senores Pharmaceuticals and its competitors. This is 36% above median its historical median of 27.36. Over the past decade, Senores Pharmaceuticals' EBITDA Margin % has ranged from 16.76 to 45.44. According to the industry distribution chart, Senores Pharmaceuticals ranks #94 out of 955 companies in the Drug Manufacturers industry, placing it in the top 9.8%.
Is Senores Pharmaceuticals' EBITDA Margin % too high?
Senores Pharmaceuticals' current EBITDA Margin % of 37.19% is 36% above median its 10-year median of 27.36. Over the past 10 years, this metric has ranged from a low of 16.76 to a high of 45.44. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Senores Pharmaceuticals' value of 37.19% is 199% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #94 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #94 out of 955 companies for EBITDA Margin %. This places Senores Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Senores Pharmaceuticals' value of 37.19% is 199% above this benchmark. Historically, Senores Pharmaceuticals' own EBITDA Margin % has ranged from 16.76 to 45.44 over the past decade. While the company's 10-year median is 27.36 vs. the industry median of 12.44, Senores Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current EBITDA Margin % of 37.19% is 199% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current EBITDA Margin % is 37.19%, which is 36% above median its own 10-year median of 27.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current EBITDA Margin % of 37.19%. The current EBITDA Margin % is 37.19%, which is 36% above median its 10-year median of 27.36 and 199% above the Drug Manufacturers industry median of 12.44. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current EBITDA Margin % is 37.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score
Get the complete analysis for NSE:SENORES
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
